Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $121 billion biotechnology leader, from the previous $460.00 to a new target of ...
Bernstein SocGen Group adjusted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), increasing it slightly from $441.00 to $444.00 while maintaining a Market Perform rating. With a ...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $459 from $450 and keeps an Equal ...
Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...